LBLisa Barroilhet

Lisa Barroilhet

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lisa Barroilhet has a total of 170 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Phase 1b breast cancer prevention clinical trial of 9cUAB30 administered prior to surgical resection

    by Helen Krontiras, Lee G. Wilke, Katina DeShong, Kimaya Chaubal, Jianqing Zhang, Paul R. Hutson, Heather Green, Thomas C. Havighurst, KyungMann Kim, Richard J. Chappell, et al.

    We performed a phase Ib clinical trial in participants with breast carcinoma evaluating the effects of the novel rexinoid 9cUAB30 orally for 14-28 days prior to surgical resection. Twenty-seven female volunteers (mean±S.D. age 63±10 years) newly diagnosed with breast cancer awaiting surgery as their initial treatment received 9cUAB30 once daily (240 mg for first 5 participants and 160 mg for the subsequent 22 participants) for 13-25 days. Comparison of breast tissue proliferation (Ki-67) at baseline and end of study revealed no significant change with results similar to participant-matched historical control samples. Secondary analysis of tissue apoptosis (Cleaved Caspase 3) observed an increase from baseline to end of study but when compared to changes exhibited by matched to historical controls, no difference was observed. Exploratory analysis of participant tissue samples by nCounter molecular profiling observed increased cytokine and decreased proliferation marker gene expression. Assessment of circulating dendritic cells demonstrated an increase in type 1 monocytic and a decrease in type 2 plasmacytic cells. 9cUAB30 plasma concentrations day of surgery were 349 ± 204 ng/ml (range 66-873). Most participants had grade 1-2 adverse events with the most common being hypertension, headache and gastrointestinal- and skin-related symptoms. Laboratory analysis observed a small but significant increase in total and LDL serum cholesterol (p<0.001). In this phase Ib clinical trial, 9cUAB30 was well tolerated with mild rexinoid-related side effects, no measurable effect upon breast tissue proliferation but encouraging exploratory effects on gene expression and circulating immune effector cells at relatively high daily rexinoid dosing.

  • Open Access

    An autologous cell-based therapeutic vaccine expressing IL6/1 fusokine drives robust anti-tumor response against ovarian cancer

    by Sejal Sharma, Rahul Das, Andrea Pennati, Catigan Hedican, Lisa Barroilhet, Manish S. Patankar, Jacques Galipeau

    Background: Cytokines are immunomodulatory proteins that play central roles in regulating immune responses and represent attractive targets for cancer therapy. However, as single agents, cytokines have shown limited clinical benefit due to systemic toxicities and a short in vivo half-life. Our group has focused on engineering fusion cytokines (fusokines) that couple two cytokines into a single biologic to reprogram immune cell responses by enforcing non-canonical receptor engagement and signaling. A chimeric IL-6/IL-1β fusokine was engineered to test the hypothesis that enforced co-engagement of IL-6 and IL-1β signaling pathways would confer a gain-of-function phenotype in T cells and promote robust anti-tumor immunity. Here, we describe the immunomodulatory properties of IL6/1 fusokine and a method to deliver this fusokine to produce inhibition of ovarian tumor growth in a pre-clinical mouse model. Methods: Lentiviral vectors encoding murine or human IL6/1 were designed using Vector Builder and expressed in either HEK293, CHO or ID8-F3 (p53 −/- ) cells depending on the downstream experiment to be conducted. IL6/1 expression was validated by ELISA and flow cytometry. Effects of human IL6/1 (hIL6/1) on T cell function (proliferation, memory phenotype, activation induced apoptosis) were monitored by flow cytometry. For in vivo studies, ID8-F3 murine ovarian cancer cells expressing mouse IL6/1 (mIL6/1) were administered intraperitoneally (I.P.) as a cell-based therapy to C57BL/6 female mice bearing established ID8-F3 luciferase tumors. Tumor progression was monitored by bioluminescence (BLI) imaging, and overall survival was evaluated. Results: hIL6/1 significantly enhanced T cell survival and selectively promoted activation and expansion of CD45RO⁺ memory T cells. mIL6/1 expressing ID8-F3 cells (ID8IL6/1) demonstrated stable transduction and sustained cytokine secretion. In vivo, ID8IL6/1 cell therapy significantly reduced tumor growth and improved overall survival compared to control groups, with 2 of 8 mice achieving complete tumor clearance. Conclusion: These findings indicate that IL6/1 fusokine enhances T cell survival and proliferation while promoting memory responses. Engineered cancer cells (ID8-F3) expressing mIL6/1 fusokine induced a strong anti-tumor response when delivered as a therapeutic vaccine in ovarian cancer mouse model. What is already known on this topic: Fusokines are a class of bifunctional proteins designed to achieve synergistic immune modulation. Previous studies in our lab have shown fusokine exhibit gain-of-function immunomodulating activity. Individually, IL-6 and IL-1β are recognized for their roles in promoting T-cell proliferation and effector function. However, the potential for a fused IL-6/1 fusokine to reprogram the immune system and elicit a superior anti-tumor response in vivo in ovarian cancer model is not yet studied. What this study adds: This study develops a novel fusion cytokine (fusokine), combining IL-6 and IL-1β, and demonstrate robust activation of T cells. In a preclinical ovarian cancer model, engineered cancer cells expressing IL6/1 used as a therapeutic vaccine showed significant tumor reduction and improved overall survival. How this study might affect research, practice or policy: This study demonstrates that in comparison to individual cytokines, fusokines have greater potential to activate T cell function and when delivered as a cell therapy, achieve clear therapeutic efficacy in an ovarian cancer model. Further translational and clinical studies may enable the development of novel and more effective fusokine cell therapy approaches for patients with ovarian cancer.

  • Benign Lesions Scored as O-RADS US v2022 4 and 5 Categories: Prevalence and Morphologic Analysis

    by Priyanka Jha, Elizabeth A. Sadowski, Akshya Gupta, Katherine E. Maturen, Krupa K. Patel-Lippmann, Hanna M. Zafar, Aya Kamaya, Neha Antil, Yang Guo, Lisa M. Barroilhet, et al.

    Solid components and multilocularity were frequently found among benign lesions scored as Ovarian-Adnexal Reporting and Data System (O-RADS) 4 or 5, with cystadenomas and cystadenofibromas being the most common benign lesions.

  • Open Access

    Atovaquone-induced therapeutic rewiring of melanoma metabolism

    by Mayra Betancourt Ponce, Alexa R. Heaton, Samantha K. Burkard, Aurora D’AMato, Nicha Boonpattrawong, Melissa C. Skala, Manish Patankar, Lisa Barroilhet


  • Open Access

    Early Detection and Prevention of Ovarian Cancer

    by Lauren Montemorano, Laura Huffman, Lisa Barroilhet

    Background/Objectives: Epithelial ovarian cancer (EOC) encompasses ovarian, fallopian tube and peritoneal malignancies. It is a deadly disease and is rarely cured when diagnosed at advanced stages. Early-stage disease is often curable, but clinicians and researchers have been stymied in their attempts to reliably screen for this disease, even in high-risk populations. Effective prevention of ovarian cancer is usually limited to the use of combined oral contraceptives and removal of the ovaries and fallopian tubes. Methods and Results: We aim to review the current guidelines and the evidence reported for both the early detection and prevention of ovarian cancer. Novel imaging techniques, biomarkers, and surgical advances will be discussed. Conclusions: This review will offer (a) an understanding of the epidemiology of EOC (b) analysis and a discussion of relevant molecular markers that might be exploited for more accurate early detection (c) medical and surgical methods to prevent ovarian cancer.


  • Open Access

    Figure S4 from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression

    by Bradley R. Corr, Elizabeth R. Woodruff, Tomomi M. Yamamoto, Kimberly R. Jordan, Thomas Danhorn, Carine Bossard, Lily L. Nguyen, Edward B. Chuong, Lars Wick, Alexandra Young, et al.

  • Open Access

    Figure S3 from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression

    by Bradley R. Corr, Elizabeth R. Woodruff, Tomomi M. Yamamoto, Kimberly R. Jordan, Thomas Danhorn, Carine Bossard, Lily L. Nguyen, Edward B. Chuong, Lars Wick, Alexandra Young, et al.

    In vivo body weight and PCA plot

  • Open Access

    Figure S5 from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression

    by Bradley R. Corr, Elizabeth R. Woodruff, Tomomi M. Yamamoto, Kimberly R. Jordan, Thomas Danhorn, Carine Bossard, Lily L. Nguyen, Edward B. Chuong, Lars Wick, Alexandra Young, et al.

  • Open Access

    Table S2 from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression

    by Bradley R. Corr, Elizabeth R. Woodruff, Tomomi M. Yamamoto, Kimberly R. Jordan, Thomas Danhorn, Carine Bossard, Lily L. Nguyen, Edward B. Chuong, Lars Wick, Alexandra Young, et al.

    Raw TOP/FOP-FLASH data from Figure 1.

  • Open Access

    Table S1 from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression

    by Bradley R. Corr, Elizabeth R. Woodruff, Tomomi M. Yamamoto, Kimberly R. Jordan, Thomas Danhorn, Carine Bossard, Lily L. Nguyen, Edward B. Chuong, Lars Wick, Alexandra Young, et al.

    Counts per million for RNA-seq